KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sarepta Therapeutics (SRPT) Operating Leases (2019 - 2025)

Sarepta Therapeutics (SRPT) has 7 years of Operating Leases data on record, last reported at $215.0 million in Q3 2025.

  • For Q3 2025, Operating Leases rose 26.49% year-over-year to $215.0 million; the TTM value through Sep 2025 reached $215.0 million, up 26.49%, while the annual FY2024 figure was $192.5 million, 36.54% up from the prior year.
  • Operating Leases reached $215.0 million in Q3 2025 per SRPT's latest filing, roughly flat from $214.4 million in the prior quarter.
  • Across five years, Operating Leases topped out at $215.0 million in Q3 2025 and bottomed at $35.2 million in Q3 2022.
  • Average Operating Leases over 5 years is $112.7 million, with a median of $129.2 million recorded in 2023.
  • Peak YoY movement for Operating Leases: crashed 48.35% in 2021, then surged 282.5% in 2023.
  • A 5-year view of Operating Leases shows it stood at $41.5 million in 2021, then surged by 38.7% to $57.6 million in 2022, then skyrocketed by 144.82% to $141.0 million in 2023, then skyrocketed by 36.54% to $192.5 million in 2024, then increased by 11.73% to $215.0 million in 2025.
  • Per Business Quant database, its latest 3 readings for Operating Leases were $215.0 million in Q3 2025, $214.4 million in Q2 2025, and $205.5 million in Q1 2025.